Position in NVS
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$1,410
-$2,714 QoQ
Shares Held
9
-66.7% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#1,598
of 1,603 holders
Holding Since
Dec 2023
10 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Stone House Investment Management, LLC holds $950,513 across 13 Drug Manufacturers - General names. NVS ranks #11 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
294 | $352,632 | |
| 2 | MRK |
Merck & Co., Inc.
|
1,638 | $210,483 | |
| 3 | ABBV |
AbbVie Inc.
|
535 | $134,627 | |
| 4 | JNJ |
Johnson & Johnson
|
393 | $99,810 | |
| 5 | AMGN |
Amgen Inc
|
258 | $93,426 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
247 | $31,205 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
187 | $10,774 | |
| 8 | AZN |
Astrazeneca PLC
|
39 | $7,395 |
All Filings in NVS
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,410 | 9 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $4,124 | 27 | Shares | Sole | 2026-04-22 | |
| 2025-12-31 | $3,722 | 27 | Shares | Sole | 2026-01-21 | |
| 2025-09-30 | $3,206 | 25 | Shares | Sole | 2025-10-27 | |
| 2025-06-30 | $2,541 | 21 | Shares | Sole | 2025-08-06 | |
| 2025-03-31 | $2,341 | 21 | Shares | Sole | 2025-05-13 | |
| 2024-09-30 | $2,415 | 21 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $2,235 | 21 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $1,934 | 20 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $2,019 | 20 | Shares | Sole | 2024-01-31 | |
| No filing history on record for this holder in this stock. | ||||||